201 related articles for article (PubMed ID: 31406331)
1. Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection.
Srikhanta YN; Hutton ML; Awad MM; Drinkwater N; Singleton J; Day SL; Cunningham BA; McGowan S; Lyras D
Nat Microbiol; 2019 Dec; 4(12):2237-2245. PubMed ID: 31406331
[TBL] [Abstract][Full Text] [Related]
2. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
5. Fate of ingested Clostridium difficile spores in mice.
Howerton A; Patra M; Abel-Santos E
PLoS One; 2013; 8(8):e72620. PubMed ID: 24023628
[TBL] [Abstract][Full Text] [Related]
6. The early stage peptidoglycan biosynthesis Mur enzymes are antibacterial and antisporulation drug targets for recurrent Clostridioides difficile infection.
Sapkota M; Marreddy RKR; Wu X; Kumar M; Hurdle JG
Anaerobe; 2020 Feb; 61():102129. PubMed ID: 31760080
[TBL] [Abstract][Full Text] [Related]
7. Conserved oligopeptide permeases modulate sporulation initiation in Clostridium difficile.
Edwards AN; Nawrocki KL; McBride SM
Infect Immun; 2014 Oct; 82(10):4276-91. PubMed ID: 25069979
[TBL] [Abstract][Full Text] [Related]
8. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Evaluation of Cephamycin-Based Antisporulation Agents targeting
Cun WY; Bate CE; Srikhanta YN; Hutton ML; Webb CT; Revitt-Mills SA; Lyras D; McGowan S; Yu H; Keller PA; Pyne SG
J Med Chem; 2024 Jan; 67(1):450-466. PubMed ID: 38112278
[TBL] [Abstract][Full Text] [Related]
10. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.
Aldape MJ; Heeney DD; Bryant AE; Stevens DL
J Antimicrob Chemother; 2015 Jan; 70(1):153-9. PubMed ID: 25151204
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin.
Kuehne SA; Dempster AW; Collery MM; Joshi N; Jowett J; Kelly ML; Cave R; Longshaw CM; Minton NP
J Antimicrob Chemother; 2018 Apr; 73(4):973-980. PubMed ID: 29253242
[TBL] [Abstract][Full Text] [Related]
12. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
Allen CA; Babakhani F; Sears P; Nguyen L; Sorg JA
Antimicrob Agents Chemother; 2013 Jan; 57(1):664-7. PubMed ID: 23147724
[TBL] [Abstract][Full Text] [Related]
13.
Zhu D; Sorg JA; Sun X
Front Cell Infect Microbiol; 2018; 8():29. PubMed ID: 29473021
[No Abstract] [Full Text] [Related]
14. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.
Gebhart D; Lok S; Clare S; Tomas M; Stares M; Scholl D; Donskey CJ; Lawley TD; Govoni GR
mBio; 2015 Mar; 6(2):. PubMed ID: 25805733
[TBL] [Abstract][Full Text] [Related]
15. Inducing and Quantifying Clostridium difficile Spore Formation.
Shen A; Fimlaid KA; Pishdadian K
Methods Mol Biol; 2016; 1476():129-42. PubMed ID: 27507338
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Chicken IgY Specific to
Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D
Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119
[No Abstract] [Full Text] [Related]
17. The Transcriptional Regulator Lrp Contributes to Toxin Expression, Sporulation, and Swimming Motility in
Chen KY; Rathod J; Chiu YC; Chen JW; Tsai PJ; Huang IH
Front Cell Infect Microbiol; 2019; 9():356. PubMed ID: 31681632
[No Abstract] [Full Text] [Related]
18. A cortex-specific penicillin-binding protein contributes to heat resistance in Clostridioides difficile spores.
Alabdali YAJ; Oatley P; Kirk JA; Fagan RP
Anaerobe; 2021 Aug; 70():102379. PubMed ID: 33940167
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.
Roder C; Athan E
Drugs R D; 2020 Sep; 20(3):209-216. PubMed ID: 32377889
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
Garneau JR; Valiquette L; Fortier LC
BMC Infect Dis; 2014 Jan; 14():29. PubMed ID: 24422950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
